Chen Fang

Study authors conducted a global, open-label, phase 3 study to report the safety and efficacy of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).

In a study presented at ACTRIMS Forum 2023, researchers assessed the efficacy of treatment regimens on disability outcomes of patients with NMOSD- and MOGAD-optic neuritis and myelitis.